Acharya A, Diaz‐Ortega JL, Tambini G, de Quadros C and Arita I (2002) Cost‐effectiveness of measles elimination in Latin America and the Caribbean: a prospective analysis. Vaccine 20: 3332–3341.
Baldwin SL, Fox CB, Pallansch MA, et al. (2011) Increased potency on an inactivated trivalent polio vaccine with oil‐in‐water emulsions. Vaccine 29: 644–649.
Bishai D, Johns B, Nair D, et al. (2011) The cost‐effectiveness of supplementary immunization activities for measles: a stochastic model for Uganda. Journal of Infectious Diseases 204 (Suppl. 1): S107–S115.
Center for Disease Control and Prevention (CDC) (2014) Media statement on newly discovered smallpox specimen, July 8, 2014. http://www.cdc.gov/media/releases/2014/s0708‐NIH.htlm accessed in March 2015.
Center for Disease Control and Prevention, CDC (1993) Recommendations of the international task force for disease eradication. MMWR Rep 1993 42(RR‐16)
Chen SY, Anderson S, Kutty PK, et al. (2011) Health care‐associated measles outbreak in the United States after an importation: challenges and economic impact. Journal of Infectious Diseases 203: 1517–1525.
Cochi S and Dowdle W (2011) Disease Eradication in the 21st Century: Implications for Global Health. Cambridge, Massachusetts: The MIT Press.
Conlon D (1998) Conference on global disease elimination and eradication as public health strategies, February 26, 1998. Conference summary. Emerging Infectious Diseases 4 (2): 349–351.
Cuttis FT, Lessler J and Metcalf CJE (2013) Measles elimination: progress, challenges and implications for rubella control. Expert Review of Vaccines 12 (8): 917–932.
Dabral M (2009) Cost‐effectiveness of supplementary immunization for measles in India. Indian Pediatrics 46: 957–962.
Dayan GH, Cairns L, Sangrujee N, et al. (2004) Cost‐effectiveness of three different vaccination strategies against measles in Zambian children. Vaccine 22: 475–484.
De Quadros CA, Andrus JK, Danovaro‐Holliday MC and Castillo‐Solórzano C (2008) Feasibility of global measles eradication after interruption of transmission in the Americas. Expert Review of Vaccines 7 (3): 355–362.
De Serres G, Markowski F, Toth E, et al. (2013) The largest measles epidemic in North America in a decade – Quebec, Canada, 2011: contribution of susceptibility, serendipity and super‐spreading events. Journal of Infectious Diseases 207 (6): 990–998.
Dietrich J, Andersen LV, Andersen P and Agger EM (2014) Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01. Plos One 9 (6): e100879.
Dowdle WR and Hopkins DR (1998) The Eradication of Infectious Diseases: Reports of the Dahlem Workshop on the Eradication of Infectious Diseases. Chichester: John Wiley & Sons.
Duintjer Tebbens RJ, Pallansch MA, Cochi SL, et al. (2011) Economic analysis of the Global Polio Eradication Initiative. Vaccine 29: 334–343.
Edejer TT, Aikins M, Black R, et al. (2005) Cost effectiveness analysis of strategies for child health in developing countries. British Medical Journal 331 (7526): 1177. http://www.bmj.com/content/331/7526/1177.full.pdf+html.
Global Measles and Rubella Strategic Plan 2012–2020 (2012) Switzerland: World Health Organization. pp. 1–42.
Global Polio Eradication Initiative (GPEI) (2013) Economic Case for Eradicating Polio.
Global Polio Eradication Initiative (GPEI) (2013a) Fact File: Polio Eradication & Endgame Strategic Plan 2013–2018. pp. 1–124. Switzerland: World Health Organization.
Global Polio Eradication Initiative (GPEI) (2013b) Polio Eradication & Endgame Strategic Plan 2013–2018. pp. 1–124. Switzerland: World Health Organization.
Hawken J and Troy SB (2012) Adjuvants and inactivated polio vaccine: a systematic review. Vaccine 30 (49): 6971–6979.
Hennessey K, William Schluter W, Wang X, et al. (2014) Are we there yet? Assessing achievement of vaccine‐preventable disease goals in WHO's Western Pacific Region. Vaccine 32: 4259–4266.
Hinman AR, Irons B, Lewis M and Kandola K (2002) Economic analyses of rubella and rubella vaccines: a global review. Bulletin of the World Health Organization 80: 264–270.
Hopkins DR (2013) Disease eradication. New England Journal of Medicine 368: 54–63.
Kennedy RB, Lane JM, Henderson DA and Poland GA (2013) Smallpox and vaccinia. In: Plotkin S, Orenstein W and Offit P (eds) Vaccines, 6th edn, pp. 718–745. Atlanda: Elsevier Inc.
Kew OM, Wright PF, Agol VI, et al. (2004) Circulating vaccine‐derived polioviruses: current state of knowledge. Bulletin of the World Health Organization 82: 16–23.
Levin A et al. (2011) Global eradication of measles: an epidemiologic and economic evaluation. Journal of Infectious Diseases 204 (Suppl. 1): S98–S106.
Masignani V, Lattanzi M and Rappuoli R (2003) The value of vaccines. Vaccine 21: S2/110–S2/113.
Metcalf CJE, Lessler J, Klepac P, Cutts FT and Grenfell BT (2012) Minimum levels of coverage needed for rubella vaccination: impact of local demography, seasonality and population heterogeneity. Epidemiology and Infection 16: 1–12.
Ogden HG (1987) CDC and the Smallpox Crusade. Washington, DC: Government Printing Office. (HHS publication no. (CDC) 87‐8400).
Okayasu H, Sutter RW, Jafari HS, Takane M and Aylward RB (2014) Affordable inactivated polivirus vaccine: strategies and progress. Journal of Infectious Diseases 210 (S1): S459–S464.
Panagiotopoulos T, Antoniadou I and Valassi‐Adam E (1999) Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review. British Medical Journal 319: 1462–1467.
Parker AA, Staggs W, Dayan GH, et al. (2006) Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States. New England Journal of Medicine 355: 447–455.
Schoenbaum SC, Hyde JN, Bartoshesky L and Crampton K (1976) Benefit‐cost analysis of rubella vaccination policy. New England Journal of Medicine 294: 306–310.
Semba RD and Bloem MR (2004) Measles blindness. Survey of Ophthalmology 49: 243–255.
Simons E, Ferrari M, Fricks J, et al. (2012) Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data. Lancet 379 (9832): 2173–2178.
Sosa N, Guerra I, Abrego L, et al. (2012) Successful public health response to four cases of imported measles in Panama. Journal of Infection in Developing Countries 6 (8): 605–610.
Stepan NL (2011) Eradication: Ridding the World of Diseases Forever? Ithaca, NY: Cornell University Press.
Thompson KM and Duintjer Tebbens RJ (2007) Eradication versus control for poliomyelitis: an economic analysis. Lancet 369: 1363–1371.
United Nations Children's Fund (UNICEF) (2011) http://www.unicef.org/supply/files/2011_Vaccine_Projection_final.pdf.
White CC, Koplan JP and Orenstein WA (1985) Benefits, risks and costs of immunization for measles, mumps and rubella. American Journal of Public Health 75 (7): 739–744.
World Health Organization/United Nations Children's Fund (WHO/UNICEF) (2010) Estimates of National Immunization Coverage. Geneva: World Health Organization. http://www.who.int/immunization_monitoring/routine/immunization_coverage/en/index4.html.
World Health Organization/United Nations Children's Fund (WHO/UNICEF) (2008) Joint Annual Measles Report 2008. http://www.measlesinitiative.org/mi‐files/Reports/Measles%20Initiative/Annual%20Reports/REVISED%20FINAL%20Measles%20AR%202008.pdf.
World Health Organization, WHO (2010a) Controlling rubella and preventing congenital rubella syndrome—global progress, 2009. Weekly Epidemiological Record 85 (42): 413–417.
World Health Organization, WHO (2010b) Global Eradication of Measles: Report by the Secretariat. http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_18‐en.pdf, May 2010.
World Health Organization, WHO (2013–2018) Polio Global Eradication Initiative. Fact File: Polio Eradication and Endgame Strategic Plan 2013–2018.
World Health Organization, WHO (2014) Media Center. Measles. Fact sheet n. 286; updated November 2014.
World Health Organization (WHO) Western Pacific Regional Committee (WPRC) (2005) Measles elimination, hepatitis B control and poliomyelitis eradication. WPR/RC56.R8.
Zhou FJ, Reef S, Massoudi M, et al. (2004) An economic analysis of the current universal 2‐dose measles‐mumpsrubella vaccination program in the United States. Journal of Infectious Diseases 189 (Suppl. 1): S131–S145.
Bärnighausen T, Bloom DE, Cafiero‐Fonseca ET and O'Brien JC (2014) Valuing vaccination. Proceedings of the National Academy of Sciences of the United States of America 111 (34): 12313–12319.
Bloom DE (2015) Valuing vaccines: deficiencies and remedies. Vaccine 33 (Suppl 2): B29–B33.
Deogaonkar R, Hutubessy R, van der Putten I, Evers S and Jit M (2012) Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries. BMC Public Health 12: 878.
Newall AT, Reyes JF, Wood JG, et al. (2014) Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses. Vaccine 32 (7): 759–765.
Ozawa S, Mirelman A, Stack ML, Walker DG and Levine OS (2012) Cost‐effectiveness and economic benefits of vaccines in low‐ and middle‐income countries: a systematic review. Vaccine 31 (1): 96–108.
Rappuoli R, Pizza M, Del Giudice G and De Gregorio E (2014) Vaccines, new opportunities for a new society. Proceedings of the National Academy of Sciences of the United States of America 111 (34): 12288–12293.